SCHEMBL4923960

SCHEMBL4923960

O=C(Nc1ccc(Cl)cc1)Nc1ccc(N2CCc3ccccc3C2)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
GAA P10253 3/20 0.54
KMT2A Q03164 3/20 0.54
CYP2C19 P33261 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
GRM1 Q13255 1/20 0.51
MAPT P10636 6/20 0.48
EPHX2 P34913 1/20 0.47
CNR1 P21554 2/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 2/20 0.47
XBP1 P17861 1/20 0.47
HTT P42858 1/20 0.47
PAX8 Q06710 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5187501 0.83 MAPT (0.65) GRM1MAPTCNR1PDGFRBKDR
SCHEMBL4919660 0.81 CNR1 (0.59) MEN1GAAKMT2ACYP2C19MAPT
SCHEMBL4920276 0.80 CNR1 (0.57) MEN1GAAKMT2ACYP2C19MAPT
SCHEMBL5176497 0.80 CNR1 (0.57) MEN1GAAKMT2ACYP2C19MAPT
SCHEMBL4922838 0.80 CNR1 (0.57) MEN1GAAKMT2ACYP2C19MAPT
SCHEMBL3425880 0.79 ALDH1A1 (0.46) MEN1KMT2ACYP2C19CYP2C9GRM1
SCHEMBL5186921 0.79 MAPT (0.57) GRM1MAPTCNR1PDGFRBKDR
SCHEMBL4926347 0.78 MAPT (0.67) MEN1KMT2AMAPTEPHX2LMNA
SCHEMBL5187618 0.78 MAPT (0.56) GRM1MAPTCNR1PDGFRBKDR
SCHEMBL4926356 0.77 EPHX2 (0.51) MEN1GAAKMT2ACYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MEN1 4843/4885GAA 1071/4885KMT2A 1905/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MEN1 4843/4885GAA 1071/4885KMT2A 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.